Health
Labcorp debuts first U.S.-made FDA-cleared rapid fentanyl urine test
Labcorp (NYSE:LH), a global leader in innovative laboratory services, has announced the launch of the Labcorp Fentanyl Urine Visual Test.
United StatesHealth
Health
Herbalife to be above guidance as Q1 preliminary sales growth hits 8%
Herbalife (NYSE:HLF) announced preliminary financial results for the first quarter of 2026 on Tuesday, reporting that net sales growth and adjusted earnings are expected to surpass the high end of its previously issued guidance.
Health
Nurix Therapeutics advances Bexobrutinib toward Phase 3 following strong Q1
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
Health
Priovant Therapeutics launches Phase 2b/3 trial of brepocitinib in lichen planopilaris
Priovant Therapeutics, a majority-owned subsidiary of Roivant Sciences (NASDAQ:ROIV), provided a significant update on its late-stage immunology pipeline on Thursday, April 2, 2026.
Health
Immunovant shares tumble as batoclimab fails primary endpoint in pair of Phase 3 TED studies
Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.
Retail
FitLife Brands reports 73% revenue surge in Q4 fueled by Irwin acquisition
FitLife Brands (NASDAQ:FTLF) announced its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, April 1, 2026. The results highlight a transformative period for the Omaha-based company, largely defined by the successful integration and rapid scaling of the Irwin acquisition.
Health
IDEXX expands canine cancer detection to UK with IDEXX Cancer Dx™ Panel launch
IDEXX Laboratories (NASDAQ:IDXX) announced on Wednesday, April 1, 2026, the official launch of the IDEXX Cancer Dx™ Panel in the United Kingdom.
Health
Cadrenal Therapeutics progresses toward Phase 3 following positive FDA end-of-Phase 2 meeting
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
C814c141 5ccb 4a42 8a1c 483d7a06deeb
Keenova Therapeutics reports record $543M Q1 revenue
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.
C814c141 5ccb 4a42 8a1c 483d7a06deeb
Xtant Medical reveals 14% revenue growth in 2025
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
Health
Veradermics reports FY 2025 results and post-IPO cash runway through 2029
Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Health
Connect Biopharma reports positive Phase 1 rademikibart data
Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.